10058-F4: Small-Molecule c-Myc Inhibitor for Apoptosis Assays

Principle and Setup: Disrupting the c-Myc/Max Axis

10058-F4 is a pioneering small-molecule c-Myc inhibitor that specifically targets the c-Myc-Max dimerization, a fundamental interaction driving oncogenic transcriptional programs. By preventing c-Myc from forming functional heterodimers with Max, 10058-F4 blocks DNA binding and downstream gene activation—most notably genes involved in cell cycle progression, metabolism, and apoptosis suppression. This mechanism has positioned 10058-F4 at the forefront of apoptosis assay development, acute myeloid leukemia research, and studies in advanced stem cell models where c-Myc plays a pivotal regulatory role.

Recent findings, such as those presented in Kotian et al., 2024, further illuminate the dual control of telomerase (TERT) expression by the MEK/ERK pathway and the c-Myc/Max transcriptional complex in pluripotent stem cells. Notably, low-dose application of a c-Myc:Max dimerization inhibitor induced rapid accumulation of repressive H3K27me3 at the TERT promoter, demonstrating the utility of precise c-Myc disruption for epigenetic and transcriptional regulation studies.

Supplied by APExBIO, 10058-F4 (10058-F4 product page) is a cell-permeable, DMSO-soluble compound with a molecular weight of 249.35 g/mol, provided as a solid for versatile experimental integration. Its rapid, dose-dependent induction of apoptosis and cell cycle arrest via the mitochondrial pathway—modulating Bcl-2 family proteins and cytochrome C release—has been validated in AML cell lines (HL-60, U937, NB-4) and in vivo prostate cancer xenograft models (DU145, PC-3).

Step-by-Step Workflow: Protocol Enhancements with 10058-F4

1. Compound Preparation and Storage

• Reconstitution: Dissolve 10058-F4 in DMSO (≥24.9 mg/mL) or ethanol (≥2.64 mg/mL). The compound is insoluble in water.
• Aliquoting: Prepare small aliquots to avoid repeated freeze-thaw cycles. Store at -20°C and use solutions promptly, as long-term storage in solution is not recommended.

2. Cell Culture and Treatment

• Model Selection: Select c-Myc-driven cell lines (e.g., HL-60, U937, NB-4 for AML; DU145, PC-3 for prostate cancer; human pluripotent stem cells for TERT regulation studies).
• Dosing: For robust apoptosis induction, treat cells with 10058-F4 at concentrations up to 100 μM for 48–72 hours. Time-course and dose-response experiments are recommended to establish optimal conditions.

3. Apoptosis and Transcriptional Assays

• Apoptosis Detection: Employ Annexin V/PI staining, caspase activity assays, or cytochrome C release ELISAs to quantify mitochondrial apoptosis pathway activation.
• Gene Expression Analysis: Use qPCR or Western blot to measure c-Myc, TERT, and Bcl-2 family protein levels post-treatment.
• Chromatin Immunoprecipitation (ChIP): To interrogate epigenetic effects, perform ChIP for H3K27me3 and H3K27ac at target gene promoters (e.g., TERT), as demonstrated in Kotian et al., 2024.

4. In Vivo Xenograft Studies

• Model Setup: Implant human prostate cancer cell lines in SCID mice.
• Administration: Deliver 10058-F4 intravenously and monitor tumor growth inhibition over time. Note: efficacy may vary between cell lines; titrate dosing for best results.

Advanced Applications and Comparative Advantages

Targeting c-Myc/Max for Oncogenic Pathway Dissection

As a c-Myc-Max dimerization inhibitor, 10058-F4 uniquely enables researchers to probe the direct transcriptional and epigenetic consequences of c-Myc disruption. In AML cell lines, apoptosis is induced in a dose-dependent manner, with significant cell death observed at 100 μM after 72 hours (referenced in multiple studies). This makes 10058-F4 particularly suited for:

• Acute myeloid leukemia research: Dissecting c-Myc-driven survival pathways and evaluating novel combination therapies.
• Prostate cancer xenograft models: Assessing c-Myc’s role in tumor maintenance and response to targeted therapies.
• Stem cell and telomerase regulation: As shown in Kotian et al., 2024, 10058-F4 can rapidly induce repressive chromatin marks at TERT, offering a powerful tool to study telomere biology and aging.

Interlinking Published Resources for Broader Context

The strategic value of 10058-F4 is further highlighted when examining the landscape of c-Myc pathway research:

• Disrupting c-Myc/Max: Strategic Insights and Translational Promise — This article complements the present workflow by providing a thorough mechanistic and translational perspective on 10058-F4, especially in the context of telomerase biology and oncology.
• 10058-F4: Small-Molecule c-Myc Inhibitor for Apoptosis Assays — Extends protocol guidance and highlights troubleshooting strategies for apoptosis research, particularly in AML and prostate cancer models.
• 10058-F4: Advanced c-Myc-Max Dimerization Inhibitor for Apoptosis Research — Offers comparative evaluation with other inhibitors and explores advanced applications in DNA repair and telomerase regulation—expanding the utility of 10058-F4 in translational research settings.

Comparative Advantages

• Pathway specificity: Directly targets the c-Myc/Max axis, minimizing off-target effects common with upstream kinase inhibitors.
• Cell permeability: Efficiently penetrates both suspension and adherent cell models, enabling broad application.
• Quantified efficacy: Documented induction of apoptosis in AML cell lines and tumor growth inhibition in vivo—providing data-driven confidence in experimental planning.

Troubleshooting and Optimization Tips

• Compound Solubility: Always dissolve 10058-F4 in DMSO or ethanol. Avoid aqueous solutions, as the compound is insoluble in water and may precipitate, reducing bioavailability.
• Cell Line Sensitivity: Sensitivity to c-Myc inhibition varies. Perform pilot dose-response studies to determine the minimum effective concentration for your cell model. For stem cells and primary cultures, start with lower doses (10–50 μM) and titrate upward as needed.
• Long-Term Storage: Use freshly prepared solutions and avoid storing working dilutions for more than 24 hours. Degradation can compromise activity and reproducibility.
• Off-Target Effects: Confirm c-Myc/Max disruption by Western blot or ChIP. For advanced studies, pair with genetic knockdown or rescue experiments for target validation.
• Assay Timing: Peak effects on apoptosis (e.g., cytochrome C release, caspase activation) are typically observed after 48–72 hours of treatment in AML models; adjust timing for other cell types accordingly.
• ChIP and Epigenetics: When investigating chromatin changes (e.g., H3K27me3 at TERT), synchronize cell treatments and include proper controls to distinguish direct effects from secondary stress responses.

Future Outlook: Expanding Horizons in c-Myc-Driven Research

The versatility of 10058-F4, as a cell-permeable c-Myc inhibitor for apoptosis research, continues to drive innovation at the interface of cancer biology, stem cell epigenetics, and telomere maintenance. The groundbreaking work by Kotian et al., 2024 demonstrates that c-Myc/Max disruption not only modulates proliferation but also triggers rapid epigenetic remodeling—a paradigm shift in our understanding of TERT regulation and cellular immortality.

As the field moves toward combinatorial strategies—integrating c-Myc/Max inhibition with kinase or epigenetic modulators—10058-F4 is poised to remain an essential tool for dissecting oncogenic networks, optimizing apoptosis assays, and developing next-generation therapies. Continued direct sourcing from APExBIO ensures batch consistency and experimental reliability for cutting-edge research. For detailed protocols, troubleshooting, and product information, visit the 10058-F4 product page.

By leveraging the unique properties of 10058-F4 in diverse models—ranging from AML and prostate cancer to pluripotent stem cells—researchers can unlock new insights into the c-Myc/Max heterodimer disruption pathway, the mitochondrial apoptosis pathway, and the epigenetic regulation of telomerase.